Clinical Trials · NCT00832091
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
- Enrollment
- 72
- Start date
- Jul 2006
- Locations
- 8 sites, Italy, Poland
- Primary endpoint
- Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days